---
title: "Novo Nordisk (NOVO) stock news, pipeline, cash and catalysts"
url: "https://aibio.space/companies/novo-nordisk/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Novo Nordisk news for investors: Novo Nordisk is a Danish drugmaker that sells diabetes and obesity medicines, led by semaglutide (Ozempic, Wegovy and the…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Novo has the cash and the pill; it needs new products to stop the U.S. slide

Novo still earns large profits from semaglutide, and the Wegovy pill is selling well. But U.S. sales are falling, its non-GLP-1 bets have disappointed, and the company now depends on Q4 approvals and licensed assets to change its direction.

Read the full desk view

aibio.space Investor Rank · Opinion

**7** /10 Positive view

Semaglutide still earns large profits and cash flow, with filed drugs facing Q4 decisions, but U.S. sales are falling and non-GLP-1 bets have disappointed.

- **Technology**: 2/2

- **Odds**: 2/2

- **Balance sheet**: 2/2

- **Risk**: 1/2

- **Momentum**: 0/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Proven but aging.** Semaglutide brands sold more than DKK 50 billion in Q2, and the Wegovy pill adds an oral version.

- **Odds**: **Good for filed drugs.** CagriSema and the 25 mg pill face U.S. decisions in Q4 2026; filed drugs are approved about 90.6% of the time.

- **Balance sheet**: **Strong cash generation.** H1 free cash flow was DKK 55.3 billion, funding a buyback of up to DKK 15 billion.

- **Main risk**: **Losing U.S.** share. U.S. sales fell 2% at constant exchange rates in Q2 as Lilly grew 48%.

- **Watch next**: **Fourth-quarter FDA decisions.** CagriSema and oral semaglutide 25 mg are due before year end.

## Top news on Novo

1. 2026-09-14 Financings [Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback](https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/) All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.

## Dates

**Q4 2026**
U.S. decision on CagriSema for obesity [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)

**Q4 2026**
U.S. decision on oral semaglutide 25 mg for type 2 diabetes [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)

**Q4 2026**
Expected closing of Hengrui HRS-1596 license [Source](https://www.globenewswire.com/news-release/2026/09/29/3370376/0/en/novo-and-hengrui-pharma-enter-exclusive-license-agreement-for-once-weekly-oral-glp-1-gip-dual-receptor-agonist-hrs-1596.html)

**First half of 2027**
HERMES and ARTEMIS phase 3 readouts for ziltivekimab; targeted U.S. launch of denecimig [Source](https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html)

## The money

H1 2026 free cash flow of DKK 55.3 billion; 2026 free cash flow guidance raised to DKK 45 billion to DKK 55 billion. The Q2 report did not state a cash balance. Buyback of up to DKK 15 billion under way. [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)

Q2 2026 sales of DKK 78.5 billion, up 7% at constant exchange rates on an adjusted basis; Ozempic DKK 31.4 billion, Wegovy injectable DKK 19.5 billion, Wegovy pill DKK 3.2 billion. [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)

## Risks on the record

- U.S. sales fell 2% at constant exchange rates in Q2 2026, and 2026 guidance calls for adjusted sales between flat and down 6%. [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)
- Pipeline setbacks: ziltivekimab missed its primary endpoint in ZEUS (HR 0.99), and Q2 included DKK 6.3 billion of impairments. [Source](https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html)
- FDA review of denecimig was extended because of manufacturing facility remediation, with no new decision date. [Source](https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html)

## Questions investors ask

### What is aibio.space's Investor Rank for Novo Nordisk?

7 out of 10, our positive view. Semaglutide still earns large profits and cash flow, with filed drugs facing Q4 decisions, but U.S. sales are falling and non-GLP-1 bets have disappointed. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What is Novo Nordisk's 2026 sales outlook?

Novo expects 2026 adjusted sales and adjusted operating profit to range from flat to down 6% at constant exchange rates. It raised that range on August 4 from declines of 4% to 12%. [Source](https://www.biospace.com/press-releases/novo-nordisk-raises-adjusted-sales-and-adjusted-operating-profit-outlook-for-2026)

### How much did the Wegovy pill sell in Q2 2026?

The Wegovy pill booked DKK 3.2 billion in second-quarter 2026 sales. Weekly U.S. prescriptions passed 265,000 in the week ending July 17. [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)

### Why did Novo Nordisk's ZEUS trial fail?

Ziltivekimab lowered the inflammation markers IL-6 and hsCRP but did not reduce heart attacks, strokes or cardiovascular deaths (hazard ratio 0.99). Serious infections were more common on the drug. [Source](https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html)

### When will the FDA decide on CagriSema?

Novo's second-quarter 2026 report lists a U.S. decision on CagriSema in the fourth quarter of 2026. [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)

### What did Novo Nordisk pay Hengrui for HRS-1596?

Novo agreed to pay $300 million upfront, with total potential value up to $2.6 billion including milestones, plus royalties. The deal is expected to close in the fourth quarter of 2026. [Source](https://www.globenewswire.com/news-release/2026/09/29/3370376/0/en/novo-and-hengrui-pharma-enter-exclusive-license-agreement-for-once-weekly-oral-glp-1-gip-dual-receptor-agonist-hrs-1596.html)

### Is Novo Nordisk a smaller reporting company?

SEC records list Novo Nordisk A/S's filer category as: Large accelerated filer. Source

### Where is Novo Nordisk headquartered?

SEC records list its business address as NOVO ALLE DK 2880, BAGSVAERD DENMARK, Denmark, 00000. Source

### When does Novo Nordisk's fiscal year end?

Novo Nordisk A/S's fiscal year ends on December 31, per SEC records. Source

### What did Novo Nordisk last file with the SEC?

Its most recent filing in our record is a 6-K filed 2026-10-19. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/353278/000117184326006685/f6k_101926.htm)

### What industry is Novo Nordisk in?

Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source

### Which other companies' news mentions Novo Nordisk?

Novo Nordisk is named in 1 of our story about other companies, most recently: "Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback" (Sep 14, 2026). [Source](https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/)

### How can I follow Novo Nordisk (NOVO B) news?

Press Follow on this page to add Novo Nordisk to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Novo Nordisk so far, in Financings. Source

## Legal and investor matters

Checked against Novo Nordisk filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

1. 2026-08-04 Litigation Novo Nordisk faces putative class actions over June 2026 IT security incident Novo Nordisk's interim report for the first half of 2026 says the company is a defendant in multiple putative class action lawsuits in the United States related to an IT security incident announced by press release on 2026-06-11. The complaints assert negligence and other claims on behalf of individuals who allege their personal and protected health information was compromised. The report names no court or case number. Status: filed [Novo Nordisk interim report H1 2026 (Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)
2. 2026-08-04 Other Novo Nordisk raises 2026 adjusted sales and operating profit outlook On 2026-08-04 Novo Nordisk said second-quarter 2026 adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11%. The company raised its full-year 2026 adjusted sales and adjusted operating profit outlook at constant exchange rates. The adjusted growth rates exclude the non-recurring impact of provision reversals related to the 340B Drug Pricing Program in the US, and adjusted operating profit also excludes DKK 6.3 billion of non-cash impairment charges. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326005184/f6k_080426.htm)
3. 2026-05-18 Litigation U.S. Supreme Court denies Novo Nordisk petition in Inflation Reduction Act suit On 2026-05-18 the U.S. Supreme Court denied Novo Nordisk's petition for certiorari seeking review of the Third Circuit's decision affirming dismissal of its lawsuit challenging the pricing provisions of the Inflation Reduction Act. The interim report for the first half of 2026 says no further appeals can be taken and the matter is closed. U.S. Supreme Court · Status: dismissed [Novo Nordisk interim report H1 2026 (Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)
4. 2026-04-03 Class action Amended complaint filed in ADR securities class action; CEO dropped as defendant On 2026-04-03 an amended complaint was filed in the securities class action in the District of New Jersey brought by a proposed class of purchasers of Novo Nordisk ADRs between 2024-11-06 and 2025-07-28. Novo Nordisk describes it as containing similar allegations to the 2025-08-01 original complaint, namely that the company misled investors about its potential to capitalise on the compounded market for GLP-1 medicines. Current CEO Maziar Mike Doustdar, a defendant in the original complaint, is not named in the amended one. Novo Nordisk does not expect a material impact. U.S. District Court for the District of New Jersey · Status: pending [Novo Nordisk interim report Q1 2026 (Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm)
5. 2026-02-04 Class action Catalent securities class action settled for amount covered by Catalent insurance Novo Nordisk's Annual Report 2025 says a securities class action filed in February 2023 in the District of New Jersey by City of Warwick Retirement System against Catalent and others settled in November 2025 for an amount fully covered through Catalent insurance policies. Novo Nordisk acquired three Catalent sites in December 2024, including a portion of any potential liability. Final court approval was anticipated in mid-2026. U.S. District Court for the District of New Jersey · Status: settled [Novo Nordisk Annual Report 2025 (Form 20-F exhibit)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm)
6. 2026-02-04 Litigation Jury returns defense verdict for Novo Nordisk in NovoSeven qui tam case A 2015 qui tam suit by a former employee alleged kickbacks and false claims relating to NovoSeven. After the Department of Justice declined to intervene, the relator and the Washington State Attorney General proceeded, and a jury returned a defense verdict for Novo Nordisk in November 2025. The Annual Report 2025 says they have appealed to the Ninth Circuit and that Novo Nordisk does not expect a material impact. U.S. Court of Appeals for the Ninth Circuit · Status: appealed [Novo Nordisk Annual Report 2025 (Form 20-F exhibit)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm)
7. 2026-01-20 Regulatory 340B ruling final: Novo Nordisk to recognise USD 4.2 billion of 340B provisions as revenue HRSA dismissed a 340B administrative dispute resolution petition against Novo Nordisk on 2025-12-04, and the decision became final on 2026-01-20 after a reconsideration deadline expired. Novo Nordisk said the legal uncertainty was resolved only after the 2025 balance sheet date and that it would recognise USD 4.2 billion of revenue, the entire amount of its 340B statutory discount provisions, in the first quarter of 2026. On 2026-02-03 it said its 2026 outlook would be positively impacted by a reversal of USD 4.2 billion of sales rebate provisions related to the 340B program. U.S. Health Resources and Services Administration [Novo Nordisk Annual Report 2025 (Form 20-F exhibit)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm)
8. 2025-11-14 Governance Novo Nordisk shareholders elect new chair and board members at extraordinary meeting At an extraordinary general meeting on 2025-11-14, Lars Rebien Sørensen was elected chair, Cees de Jong vice chair, and Britt Meelby Jensen and Stephan Engels members of the board. Chair Helge Lund, vice chair Henrik Poulsen and five other directors stepped down. The board had called the meeting on 2025-10-21 after it could not reach a common understanding with the Novo Nordisk Foundation, which controls the majority of votes, on board composition. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325007325/f6k_111425.htm)
9. 2025-10-30 Other Novo Nordisk confirms unsolicited proposal to acquire Metsera On 2025-10-30 Novo Nordisk confirmed it had submitted an unsolicited proposal to acquire Metsera, Inc. at 56.50 USD per share in cash, an approximate equity value of 6.5 billion USD, plus contingent value rights of up to 21.25 USD per share tied to clinical and regulatory milestones. The announcement does not say whether Metsera accepted the proposal. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325006795/f6k_103025.htm)
10. 2025-10-09 Other Novo Nordisk agrees to acquire Akero Therapeutics for 54 USD per share plus CVR On 2025-10-09 Novo Nordisk announced a definitive agreement to acquire Akero Therapeutics, which is developing the FGF21 analogue efruxifermin for MASH. The price is 54 USD per share in cash at closing, about 4.7 billion USD, plus a contingent value right of 6 USD per share, about 0.5 billion USD. The Q3 2025 report said the Akero deal was included in cash flow guidance, contingent on closing timing. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325006370/f6k_100925.htm)
11. 2025-09-10 Other Novo Nordisk plans to cut about 9,000 roles with DKK 8 billion restructuring cost On 2025-09-10 Novo Nordisk announced a company-wide transformation under which it intends to reduce its global workforce by approximately 9,000 of 78,400 positions, with around 5,000 in Denmark. It expects DKK 8 billion of annualised savings by the end of 2026 and one-off restructuring costs of DKK 8 billion. It updated its 2025 operating profit growth outlook to 4 to 10 percent at constant exchange rates. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325005809/f6k_091025.htm)
12. 2025-08-01 Class action Securities class action filed over GLP-1 compounding disclosures On 2025-08-01 a class action was filed in the District of New Jersey against Novo Nordisk, former CEO Lars Fruergaard Jørgensen, CEO Maziar Mike Doustdar, CFO Karsten Munk Knudsen and executive Dave Moore, for purchasers of Novo Nordisk ADRs between 2025-05-07 and 2025-07-28. The complaint alleges the company misled investors about the compounded GLP-1 market. Novo Nordisk does not expect a material impact. U.S. District Court for the District of New Jersey · Status: pending [Novo Nordisk Annual Report 2025 (Form 20-F exhibit)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm)
13. 2025-07-29 Governance Novo Nordisk lowers 2025 outlook and names Doustdar CEO On 2025-07-29 Novo Nordisk lowered its 2025 outlook to sales growth of 8 to 14 percent and operating profit growth of 10 to 16 percent at constant exchange rates. The same day it named Maziar Mike Doustdar president and chief executive officer, effective 2025-08-07, succeeding Lars Fruergaard Jørgensen. A securities class action filed 2025-08-01 covers purchases of Novo Nordisk ADRs from 2025-05-07 to 2025-07-28. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325004760/f6k_072925.htm)
14. 2025-05-16 Governance Novo Nordisk announces CEO Jørgensen will step down On 2025-05-16 Novo Nordisk announced that Lars Fruergaard Jørgensen would step down as CEO by mutual agreement with the board, and Lars Rebien Sørensen, chair of the Novo Nordisk Foundation, would join the board as an observer. The company said the changes were made in light of recent market challenges and the share price since mid-2024, and that the Foundation had expressed a wish to increase its board representation. [Novo Nordisk Form 6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325003274/f6k_051625.htm)
15. 2025-01-24 Class action Securities class action filed over REDEFINE-1 trial disclosures On 2025-01-24 a class action was filed in the District of New Jersey against Novo Nordisk, former CEO Lars Fruergaard Jørgensen and R&D chief Martin Holst Lange for purchasers of Novo Nordisk ADRs between 2022-11-02 and 2024-12-19. The Annual Report 2025 says the suit relates to REDEFINE-1 and alleges the company failed to disclose the nature of the dosages given to study patients. Novo Nordisk does not expect a material impact. U.S. District Court for the District of New Jersey · Status: pending [Novo Nordisk Annual Report 2025 (Form 20-F exhibit)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Semaglutide (Ozempic, Wegovy, Wegovy pill) | Type 2 diabetes, obesity, MASH | Marketed [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) |
| CagriSema | Obesity | Under FDA review; U.S. decision listed for Q4 2026 [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) |
| Oral semaglutide 25 mg (Ozempic pill) | Type 2 diabetes | Under FDA review; decision expected Q4 2026 [Source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) |
| Denecimig | Hemophilia A | FDA review extended; positive CHMP opinion Sept 2026 [Source](https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html) |
| Ziltivekimab | Heart failure (HERMES), acute heart attack (ARTEMIS) | Phase 3; ZEUS failed July 2026 [Source](https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html) |
| HRS-1596 (licensed from Hengrui) | Obesity, type 2 diabetes | Phase 1-ready; deal closing expected Q4 2026 [Source](https://www.globenewswire.com/news-release/2026/09/29/3370376/0/en/novo-and-hengrui-pharma-enter-exclusive-license-agreement-for-once-weekly-oral-glp-1-gip-dual-receptor-agonist-hrs-1596.html) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Novo's '9 in 10' liver claim rests on 23 of 26 patients, and its 'raised outlook' still points to flat or lower sales

Novo's Q2 report and its later announcements are internally consistent, and the company states the bad news on ziltivekimab and denecimig plainly. The gaps are in framing: the headline leads with adjusted profit and a raised outlook that still points to flat or lower sales, and the liver-fat release headlines a post hoc figure from 26 patients. The Q2 report's legal section lists IT-incident class actions and patent suits, not securities suits.

1. Science · weight high '9 in 10' liver fat result is 23 of 26 patients in a post hoc analysis **The company said:** "9 in 10 achieved normal liver fat levels: Among participants with liver fat above 5%, 88.5% in the pooled group of people taking Wegovy® (injectable semaglutide 7.2 and 2.4 mg) achieved normal liver fat levels below 5% by week 72" [source](https://www.globenewswire.com/news-release/2026/10/01/3372708/0/en/novo-s-wegovy-semaglutide-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-easd2026.html) **The record says:** The same release says it presents "post hoc analysis of data from a STEP UP trial sub-population with 55 participants", that "26 participants entered the trials with liver fat above 5% and 88.5% of them" reached the below-5% threshold, which the release counts as 23 participants, and that the analysis "was not a pre-specified primary or secondary endpoint of the parent trials". It also says "Semaglutide 7.2 mg is not being investigated for the treatment of MASH." [source](https://www.globenewswire.com/news-release/2026/10/01/3372708/0/en/novo-s-wegovy-semaglutide-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-easd2026.html) **Our view:** The headline is arithmetically right and the small numbers are in the release. But 23 patients in an exploratory subgroup, with no stated comparison to placebo for this figure, is thin support for a headline about 9 in 10 adults. It also shows an effect on a liver fat measure, not on MASH outcomes.
2. Press release vs filing · weight medium 'Raises outlook' headline leads with adjusted figures **The company said:** "Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook" [source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) **The record says:** The same report says "Q2 2026 reported operating profit decreased by 16% at CER, with growth negatively impacted by the US 340B rebate provision reversal in Q2 2025 as well as non-cash impairment charges of DKK 6.3 billion in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion)." The raised outlook reads: "Adjusted sales growth for 2026 is now expected to be 0% to -6% at CER and adjusted operating profit growth is now expected to be 0% to -6% at CER." [source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) **Our view:** The adjustments are defined and reconciled in the report, so this is a framing point, not a contradiction. Reading only the headline, one would miss that reported operating profit fell and that even the raised guidance is a range of flat to down 6%.
3. Press release vs filing · weight medium Denecimig delay: the facility remediation news came after the Q2 report **The company said:** "Denecimig US & EU decision" [source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) **The record says:** The October 2 announcement says the FDA "has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency's review" and that Novo had anticipated "a regulatory decision in the third quarter of 2026". It adds that "the FDA performed a pre-license inspection of the manufacturing site and provided feedback" after the September 2025 submission, without giving the date of that feedback. [source](https://www.sec.gov/Archives/edgar/data/353278/000117184326006374/f6k_100226.htm) **Our view:** The Q2 report's milestone table lists a denecimig decision for 2026 and does not mention facility remediation. The filing does not say when Novo learned of the FDA's feedback, so we cannot say the Q2 report was out of date. The announcement is clear that the FDA found no efficacy or safety deficiencies.
4. Science · weight low ZEUS was a clean negative, with an impairment still to come **The company said:** "this did not translate into major adverse cardiovascular events (MACE) risk reduction versus placebo in people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11)" [source](https://www.sec.gov/Archives/edgar/data/353278/000117184326005109/f6k_073126.htm) **The record says:** ClinicalTrials.gov lists ZEUS (NCT05021835) as randomized, quadruple-masked, with 6,385 actual participants and time to first 3-point MACE as the primary outcome. The announcement says ZEUS "will not impact Novo Nordisk's previously communicated adjusted operating profit outlook for 2026 but will result in a non-cash impairment charge in Q3 2026". [source](https://clinicaltrials.gov/study/NCT05021835) **Our view:** The result is stated plainly: well-designed trial, no effect, and a higher proportion of people on ziltivekimab with serious infections. The announcement says ZEUS will not change the adjusted operating profit outlook but will bring a non-cash impairment charge in Q3 2026.
5. Legal and disclosure record · weight medium IT-incident class actions and patent suits disclosed **The record says:** Legal matters in the Q2 2026 report: "Novo Nordisk is a defendant in multiple putative class action lawsuits in the US related to an IT security incident about which the company issued a press release on 11 June 2026." It also lists a Sandoz suit filed on 30 June 2026 in the Unified Patent Court (Milan Central Division) seeking revocation of a semaglutide patent, and a false advertising suit Novo filed against Eli Lilly on 21 July 2026 in federal court in New Jersey. [source](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) **Our view:** These are matters Novo discloses itself. The legal section does not list a securities class action, and the report does not quantify exposure from the IT-incident suits.

Documents we compared

- [Novo Nordisk Q2 2026 financial report (Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) 2026-08-04
- [Novo Nordisk ZEUS company announcement (Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000117184326005109/f6k_073126.htm) 2026-07-31
- [Novo Nordisk denecimig BLA update (Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000117184326006374/f6k_100226.htm) 2026-10-02
- [Novo Nordisk Wegovy liver fat release (EASD 2026)](https://www.globenewswire.com/news-release/2026/10/01/3372708/0/en/novo-s-wegovy-semaglutide-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-easd2026.html) 2026-10-01
- [Novo Nordisk Form 20-F for 2025](https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm) 2026-02-04
- [ClinicalTrials.gov NCT05021835 (ZEUS)](https://clinicaltrials.gov/study/NCT05021835) 2026-09-28

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OMXCOP:NOVO_B on TradingView](https://www.tradingview.com/symbols/OMXCOP-NOVO_B/).

## SEC filings and registration

- **SEC name**: Novo Nordisk A S

- **CIK**: 353278

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: NVO (NYSE), NONOF (OTC)

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: NOVO ALLE DK 2880, BAGSVAERD DENMARK, Denmark, 00000

- **Phone**: 4544448888

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006685/f6k_101926.htm) filed 2026-10-19
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006585/f6k_101226.htm) filed 2026-10-13
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006440/f6k_100526.htm) filed 2026-10-06
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006374/f6k_100226.htm) filed 2026-10-05
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006248/f6k_092826.htm) filed 2026-09-28
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006128/f6k_092126.htm) filed 2026-09-21
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006088/f6k_091726.htm) filed 2026-09-17
- [6-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326006038/f6k_091426.htm) filed 2026-09-15

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/novo-nordisk/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Novo Nordisk (NOVO) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/novo-nordisk/